In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in both long-term intracellular culture and spot and phage assays

The two sets of studies, showing confirmed MAP-killing effect and comparability to RHB-104, led by Professor Tim Bull from City St George's University of London, and Prof Irene Grant, Professor of Microbiology and Food Safety, Queen's University Belfast and Dr Hannah Dane, further support development of RHB-204's potential in MAP-related Crohn's disease

In its positive Phase 3 study, RHB-104 met the primary endpoint with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone in treating Crohn's disease, compared to the placebo (standard of care only) group (p = 0.0048)1

RHB-2042, a proprietary next-generation oral optimized formulation of RHB-1043, designed for reduced toxicity and side effects and enhanced patient adherence, employs a differentiated, MAP-targeted approach to the treatment of Crohn's disease 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.